Aton Biotech, a subsidiary of Henlius, is a Shanghai-based CDMO providing cell line development and cell bank construction and verification to support biologic production. The company provides comprehensive CDMO and biomanufacturing services, including process and analytical method development, clinical and commercial scale manufacturing, stability studies, and IND and NDA filing support. With over 700 commercial batches, 130+ tox and clinical batches, 50+ INDs approved globally, 99% commercial batch success rate, and 90+ successful audits, Aton specializes in the Chinese market while maintaining a global client base.